ABC - AmerisourceBergen Corporation

NYSE - NYSE Delayed Price. Currency in USD
95.34
+0.94 (+1.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close94.40
Open94.70
Bid95.46 x 1000
Ask95.90 x 1400
Day's Range93.61 - 95.60
52 Week Range72.06 - 97.50
Volume1,582,133
Avg. Volume1,871,477
Market Cap19.392B
Beta (5Y Monthly)0.61
PE Ratio (TTM)12.57
EPS (TTM)7.59
Earnings DateJul 30, 2020 - Aug 03, 2020
Forward Dividend & Yield1.68 (1.78%)
Ex-Dividend DateMay 15, 2020
1y Target Est97.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
4% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Are Nibbling On AmerisourceBergen Corporation (ABC)
    Insider Monkey

    Hedge Funds Are Nibbling On AmerisourceBergen Corporation (ABC)

    In this article we will check out the progression of hedge fund sentiment towards AmerisourceBergen Corporation (NYSE:ABC) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]

  • Top Stocks for June 2020
    Investopedia

    Top Stocks for June 2020

    NRG Energy Inc.: NRG Energy is an integrated power company that produces, sells, and distributes energy and provides energy services in the U.S. NRG reported a 75% decline in net income on a 7% drop in revenue in Q1 2020, which ended March 31, 2020. Vornado Realty Trust: Vornado Realty Trust is a real estate investment trust (REIT) that owns office, retail, merchandise mart properties, and other real estate and related investments. The company reported a 48% decline in funds from operations (FFO) per diluted share for Q1 2020, which ended March 31, 2020.

  • With M&A Hit, Wall Street Bankers Keep Busy With Stock Sales
    Bloomberg

    With M&A Hit, Wall Street Bankers Keep Busy With Stock Sales

    (Bloomberg) -- Wall Street bankers are a lot less busy these days, what with the pandemic-induced drop-off in mergers and acquisitions and initial public offerings.But there’s a gritty, less glamorous dealmaking realm that has held up, and it’s helping banks offset some of that lost M&A and IPO revenue. A variety of companies, looking for liquidity in the weak economy, are selling off big stakes they’ve long held in public corporations.The latest came Monday when French pharmaceutical giant Sanofi launched a $13 billion sale of its 16-year-old, 21% stake in Regeneron Pharmaceuticals Inc. Regeneron, a New York-based biopharmaceutical firm, agreed to buy back about $5 billion of stock while the remaining $7 billion was sold to public investors in the largest public equity offering in the heath-care industry on record, according to data compiled by Bloomberg.Sanofi’s move came a few weeks after the pandemic’s first big deal of this kind, PNC Financial Services Group Inc.’s sale of its quarter-century-old stake of more than $13 billion in BlackRock Inc. The sale was the second-largest equity offering in the U.S. since Alibaba Group Holding Ltd.’s $25 billion IPO in 2014, according to data compiled by Bloomberg.PNC’s BlackRock stake was picked up by existing investors including Wellington Management, Capital Group Cos. and Fidelity Investments, according to people familiar with the matter. At least four state investment vehicles from the Middle East also took part in the offering, the people said.More such sales are coming. SoftBank Group Corp. raised $11.5 billion from transactions related to its stake in Alibaba Group Holding Ltd. which it bought in 2000, and another $2.9 billion capitalizing a 5% stake in its wireless arm. It is also closing in on a deal to sell its roughly 25% T-Mobile US Inc. stake, worth about $20 billion, with a portion being sold to Deutsche Telekom AG, people familiar with the matter have said.These transactions so far account for some of the biggest-ever announced of their kind. All told, there’s been $80.6 billion over 21 secondary offerings announced this year, which beats $53.1 billion over 36 such deals during the same period last year, according to data compiled by Bloomberg.That compares with a 33% drop to $22 billion in volume this year for IPOs in the U.S., the data shows. M&A activity involving U.S.-based targets plummeted 62% during the same period, sinking to $241 billion, according to the data.For Wall Street, the secondary offerings aren’t as lucrative as other dealmaking but they require less work. Banks usually receive about 1% to 2% of the deal size for advisers fees, compared with 5% to 7% for handling an IPO. But IPOs often involve intensive road shows lasting weeks.Jim Cooney, head of equity capital markets for the Americas at Bank of America Corp., said selling stakes can make sense in the current economy. “The market prefers that companies stick to their core mission and monetize non-strategic assets before selling their own equity,” he said.The offerings mark another way that companies, distressed or not, have been hunting for liquidity since the beginning of the pandemic. Some have drawn down revolving credit lines, sold bonds or new shares and sold stakes to private equity firms. Investors have been willing buyers of shares, attracted by the discounts since shares are marketed at prices below where the stock is trading.These stake sales have investors speculating on what holdings could be unwound next. Here are some sizable ones to watch based on Bloomberg’s data. Bloomberg News isn’t aware of talks about potential sales of these stakes.SoftBank, UberSoftBank is Uber Technologies Inc.’s largest shareholder with a 13% stake worth $7.7 billion. The Japanese conglomerate, led by founder Masayoshi Son, forecasts an operating loss of 1.4 trillion yen ($13 billion) for the fiscal year ended in March after writing down values of the Vision Fund’s investments including WeWork and OneWeb, a satellite operator that filed for bankruptcy.While it isn’t SoftBank’s oldest or most sizable investment, it could help to recoup some losses.Walgreens Boots, AmerisourceBergenWalgreens Boots Alliance Inc. is the largest shareholder in AmerisourceBergen Corp. with a 28% stake, worth about $5.3 billion. AmerisourceBergen recently made an offer to buy the Walgreens pharmaceutical wholesale division, Reuters reported earlier this month.The news had analysts speculating it could be part of a transaction related to Walgreens exiting part of its stake in AmerisourceBergen. The two companies first saw their paths intertwine in 2013 through a $400 million distribution deal that was supposed to last a decade.Nestle, L’OrealSanofi’s deal to sell Regeneron stock also had analysts speculating it could buy back L’Oreal SA’s 9.4% stake in the drug company.That, in turn, raises the possibility that L’Oreal would buy back a 23% stake worth $35.5 billion that Nestle SA holds in the French cosmetics maker. Since this is a 40-year plus relationship, the deal idea has been long pitched by bankers. Over the years, both sides have said that the investment is long-term.HKEx, Kweichow MoutaiHong Kong Exchanges & Clearing Ltd., owner of the Hong Kong Stock Exchange, has a 8.5% stake worth $20 billion in distiller Kweichow Moutai Co.Kweichow Moutai has become a favorite stock in mainland China, and is up 15% this year, while the Shanghai Shenzhen CSI 300 Index fell 6.7%. Cashing out could help fuel HKEx’s ambitions as a dealmaker. It made a surprise bid for the London Stock Exchange last year.Mondelez, Dr PepperMondelez International Inc., the maker of Oreo cookies and Triscuit crackers, holds about about 13% of Keurig Dr Pepper, following a deal in 2018 when Keurig took control of the soda maker. In early March, right as the pandemic led to lockdowns in North America, Mondelez, and another investor connected to JAB Holdings BV called Maple Holdings BV,sold a $1.1 billion stake in Dr Pepper.The broader question for investors is whether Mondelez could sell more of its shares, Bank of America analyst Bryan Spillane said at the time. Mondelez could tap its equity stakes as a source of liquidity to fund acquisitions, he said.Coke, MonsterThe Coca-Cola Co. owns more than 18% of Monster Beverage Corp.’s stock, making it the Corona, California-based company’s largest shareholder, and Monster also uses Coke’s distribution network. While Coke took the minority stake back in 2014 in a push to capitalize on promising new brands, the beverage giant is getting more aggressive with its own offerings, which has sparked tensions with Monster. Analysts have been trying to figure out what Coke’s energy products mean for the future of the partnership.Liberty Broadband, CharterA 26% stake in Charter Communications Inc. has become a crown jewel for John Malone’s Liberty Broadband Corp. which has guided the company on acquisitions since it invested in 2013. But Malone, a savvy dealmaker, has not stopped reshaping his portfolio even in a pandemic and helped pull off a merger of Liberty Global’s U.K. business with Telefonica SA’s earlier this month.(Updates with BlackRock investors in fifth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • AmerisourceBergen Selected by Deciphera Pharmaceuticals to Support QINLOCK™
    Business Wire

    AmerisourceBergen Selected by Deciphera Pharmaceuticals to Support QINLOCK™

    AmerisourceBergen, a global healthcare solutions leader, announced today that it has been selected by Deciphera Pharmaceuticals (Deciphera) to support QINLOCK (ripretinib). AmerisourceBergen is providing a unified commercialization approach for QINLOCK which was approved by the U.S. Food and Drug Administration (FDA) on Friday, May 15, 2020. QINLOCK is an orally administered kinase switch control inhibitor approved for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

  • Thomson Reuters StreetEvents

    Edited Transcript of ABC earnings conference call or presentation 7-May-20 12:30pm GMT

    Q2 2020 AmerisourceBergen Corp Earnings Call

  • Top Health Care Stocks for June 2020
    Investopedia

    Top Health Care Stocks for June 2020

    Health care, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The health care sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and health care providers. Health care stocks, as represented by the Health Care Select Sector SPDR ETF (XLV), have outperformed the broader market, providing investors with a total return of 16.3% compared to the S&P 500's total return of 5.9% over the past 12 months. In 2020, health care stocks have recouped nearly all of their losses since their March plunge while the broader market continues to suffer from the global coronavirus pandemic. The market performance numbers and the statistics in the tables in this story are as of May 20.

  • Business Wire

    AmerisourceBergen Closes $500 Million Senior Note Offering

    AmerisourceBergen Corporation (NYSE: ABC) today announced the closing of its public offering of $500 million aggregate principal amount of its 2.800% Senior Notes due May 15, 2030 (the "Notes"), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement AmerisourceBergen filed with the Securities and Exchange Commission (the "SEC") on November 20, 2018.

  • Barrons.com

    Buy Drug Distributors’ Stocks Now, Analyst Says. McKesson and 2 More Potential Winners

    The Covid-19 downturn may be an opportunity for the three big U.S. drug distributors, UBS analyst Kevin Caliende says.

  • Business Wire

    AmerisourceBergen Prices $500 Million 2.800% Senior Notes Due 2030

    AmerisourceBergen Corporation (NYSE: ABC) today announced that it priced $500 million aggregate principal amount of its 2.800% Senior Notes due May 15, 2030 (the "Notes"), in an underwritten registered public offering. The offering is being made pursuant to an effective shelf registration statement AmerisourceBergen filed with the Securities and Exchange Commission (the "SEC") on November 20, 2018. The offering is expected to close on May 19, 2020, subject to customary closing conditions. AmerisourceBergen intends to use the net proceeds from the offering to redeem all of its 3.500% Senior Notes due November 15, 2021 and for general corporate purposes.

  • Moody's

    AmerisourceBergen Corporation -- Moody's rates AmerisourceBergen's new senior unsecured bonds at Baa2

    Moody's Investors Service ("Moody's") assigned a Baa2 rating to AmerisourceBergen Corporation's ("AmerisourceBergen") new senior unsecured bonds. Moody's expects that proceeds from the company's new $500 million bond issuance will be used for general corporate purposes, including refinancing activities.

  • AmerisourceBergen Corporation (NYSE:ABC) Passed Our Checks, And It's About To Pay A US$0.42 Dividend
    Simply Wall St.

    AmerisourceBergen Corporation (NYSE:ABC) Passed Our Checks, And It's About To Pay A US$0.42 Dividend

    It looks like AmerisourceBergen Corporation (NYSE:ABC) is about to go ex-dividend in the next 2 days. You can purchase...

  • S&P 500 and Nasdaq Gain on Monday
    GuruFocus.com

    S&P 500 and Nasdaq Gain on Monday

    Coty shares sink as revenue declined due to pandemic Continue reading...

  • Infectious-disease doctors ask government to explain how it decides who gets Gilead’s remdesivir
    MarketWatch

    Infectious-disease doctors ask government to explain how it decides who gets Gilead’s remdesivir

    Within a week of the Food and Drug Administration authorization of remdesivir as a COVID-19 treatment, clinicians are pushing the Trump administration to clarify how it is selecting which hospitals get access to the drug.

  • AmerisourceBergen Corp (ABC) Q2 2020 Earnings Call Transcript
    Motley Fool

    AmerisourceBergen Corp (ABC) Q2 2020 Earnings Call Transcript

    Good morning, and thank you all for joining us for this conference call to discuss AmerisourceBergen's Fiscal 2020 Second Quarter results. On today's call, we will be discussing non-GAAP financial measures.

  • Reuters

    Doctors want details on federal distribution of Gilead coronavirus drug

    The Infectious Disease Society of America (IDSA) is asking for more information on the federal government's plan for deciding how and where to supply the only drug so far shown to help patients infected with the novel coronavirus. The U.S. Food and Drug Administration on Friday gave emergency use authorization to Gilead Sciences Inc's remdesivir for patients with severe COVID-19 - the disease caused by the coronavirus - clearing the way for broader use in more hospitals around the United States. The federal government began distributing the drug this week.

  • The Case For AmerisourceBergen Corporation (NYSE:ABC): Could It Be A Nice Addition To Your Dividend Portfolio?
    Simply Wall St.

    The Case For AmerisourceBergen Corporation (NYSE:ABC): Could It Be A Nice Addition To Your Dividend Portfolio?

    Is AmerisourceBergen Corporation (NYSE:ABC) a good dividend stock? How can we tell? Dividend paying companies with...

  • AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates
    Zacks

    AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates

    AmerisourceBergen's (ABC) fiscal second-quarter earnings benefit from segmental growth.

  • AmerisourceBergen (ABC) Tops Q2 Earnings and Revenue Estimates
    Zacks

    AmerisourceBergen (ABC) Tops Q2 Earnings and Revenue Estimates

    AmerisourceBergen (ABC) delivered earnings and revenue surprises of 5.26% and 3.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • MarketWatch

    AmerisourceBergen profit and revenue rise above expectations, but cuts full-year outlook

    AmerisourceBergen Corp. reported Thursday fiscal second-quarter profit and revenue that rose above expectations, as the pharmaceutical distribution business got a boost from the COVID-19 pandemic, but the company lowered its full-year outlook. The drug products company also announced a new $500 million stock repurchase program and declared a regular quarterly dividend of 42 cents a share. Net income rose to $960.3 million, or $4.64 a share, from $27.1 million, or 13 cents a share, in the year-ago period, due primarily to tax benefits. Excluding non-recurring items, adjusted earnings per share rose 13.7% to $2.40, above the FactSet consensus of $2.27. Revenue grew 9.5% to $47.42 billion, above the FactSet consensus of $45.94 billion, as pharmaceutical distribution services revenue rose 9.3% to $45.6 billion to beat expectations of $44.44 billion. For 2020, the company cut its guidance ranges for adjusted EPS to $7.35 to 7.65 from $7.55 to $7.80 and for revenue growth to the low- to mid-single digit percentage range from the mid-to high-single digit range. The FactSet consensus for 2020 revenue of $188.8 billion implies 5.1% growth. The stock, which was still inactive in premarket trading, has gained 0.6% year to date while the S&P 500 has lost 11.8%.

  • Business Wire

    AmerisourceBergen Reports Fiscal 2020 Second Quarter Results

    AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2020 second quarter ended March 31, 2020, revenue increased 9.5 percent to $47.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $4.64 for the March quarter of fiscal 2020, compared to $0.13 in the prior year quarter. Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased 13.7 percent to $2.40 in the fiscal second quarter.

  • Medical Products Stock Earnings on May 7: BDX, ABC & More
    Zacks

    Medical Products Stock Earnings on May 7: BDX, ABC & More

    Medical Product companies have partially mitigated the impact of the pandemic with the massive adoption of COVID-19 related healthcare-support products and services.

  • What's in Store for AmerisourceBergen's (ABC) Q2 Earnings?
    Zacks

    What's in Store for AmerisourceBergen's (ABC) Q2 Earnings?

    AmerisourceBergen's (ABC) fiscal second-quarter results likely to reflect solid performance at Pharmaceutical Distribution.

  • Exclusive: AmerisourceBergen eyes Walgreens' drug distribution business - sources
    Reuters

    Exclusive: AmerisourceBergen eyes Walgreens' drug distribution business - sources

    Walgreens owns about 27% of AmerisourceBergen and is its biggest customer. The two companies have explored various possibilities for combining operations in recent years, including a sale of AmerisourceBergen to Walgreens, on the theory that their drug distribution businesses would be better positioned to withstand competitive price pressures through even bigger scale. The coronavirus pandemic has weighed on Walgreens' retail business since then, however.

  • AmerisourceBergen (ABC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
    Zacks

    AmerisourceBergen (ABC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    AmerisourceBergen (ABC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • How AmerisourceBergen is maintaining the drug supply amid coronavirus
    Yahoo Finance Video

    How AmerisourceBergen is maintaining the drug supply amid coronavirus

    AmerisourceBergen CEO Steven Collis joins Yahoo Finance’s Alexis Christoforous and Brian Sozzi to discuss how coronavirus has impacted the drug supply in the United States.